InxMed Co., Ltd.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Organon Will Market Lilly’s Emgality, R

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas To Select Up To Five Targ

Venture capital investors continue to show their enthusiasm for drug development, despite the relative pessimism of their peers investing in publicly traded biopharmaceutical companies, by putting the

Venture capital and private equity investors have recently reignited their interest in Chinese biotechs focused on nucleic acid platforms such as messenger RNA-based therapeutics, with four biotechs i